Ifenprodil hemitartrate
(Synonyms: 酒石酸艾芬地尔) 目录号 : GC10471An NMDA receptor antagonist
Cas No.:23210-58-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ifenprodil is a selective antagonist of NMDA receptors that contain NR2B subunits (IC50 = 0.3 µM) and displays 150-fold weaker activity at those bearing NR2C or NR2D subunits.[1] Ifenprodil also acts as a potent ligand at receptors for σ1, emopamil binding proteins, and their σ-like, fungal counterpart ERG2 (Kis = 2, 5, and 1 nM).[2] This compound has been described as an α-adrenergic vasodilator, but is also reported to constrict cerebrovascular smooth muscle in vitro (EC50 = 2.4 µM).[3]
Reference:
[1]. Bräuner-Osborne, H., Egebjerg, J., Nielsen, E.O., et al. Ligands for glutamate receptors: Design and therapeutic prospects J. Med. Chem. 43(14), 2609-2645 (2000).
[2]. Laggner, C., Schieferer, C., Fiechtner, B., et al. Discovery of high-affinity ligands of σ1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening J. Med Chem. 48(15), 4754-4764 (2005).
[3]. Young, A.R., Bouloy, M., Boussard, J.F., et al. Direct vascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels Journal of Cerebral Blood Flow and Metabolism 1(1), 117-128 (1981).
Cas No. | 23210-58-4 | SDF | |
别名 | 酒石酸艾芬地尔 | ||
化学名 | 4-((1R,2S)-2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol hemi((2R,3R)-2,3-dihydroxysuccinate) | ||
Canonical SMILES | C[C@@](N1CCC(CC2=CC=CC=C2)CC1)([H])[C@@](O)([H])C3=CC=C(O)C=C3.C[C@@](N4CCC(CC5=CC=CC=C5)CC4)([H])[C@@](O)([H])C6=CC=C(O)C=C6.O[C@](C(O)=O)([H])[C@](O)([H])C(O)=O | ||
分子式 | C21H27NO2.½C4H6O6 | 分子量 | 400.49 |
溶解度 | DMF: 50 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 1 mg/ml | 储存条件 | Store at RT |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4969 mL | 12.4847 mL | 24.9694 mL |
5 mM | 0.4994 mL | 2.4969 mL | 4.9939 mL |
10 mM | 0.2497 mL | 1.2485 mL | 2.4969 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。